Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Izervay is a prescription complement inhibitor containing avacincaptad pegol. It is indicated for geographic atrophy secondary to age-related macular degeneration. The intravitreal formulation contains 20 mg per mL and each labeled dose contains 2 mg in 0.1 mL.
read more about izervay ...Avacincaptad pegol is a PEGylated RNA aptamer that binds to and inhibits complement protein C5. C5 inhibition reduces cleavage to C5a and C5b and decreases formation of the membrane attack complex.
Izervay is used in patients with geographic atrophy secondary to age-related macular degeneration. Safety and efficacy are not established in pediatric patients. Ocular or periocular infection and active intraocular inflammation are contraindications.
The recommended dose is 2 mg by intravitreal injection into each affected eye once monthly, approximately every 28 days with a seven-day window in either direction. Administration is performed by a qualified physician using aseptic technique.
Intravitreal treatment can be associated with endophthalmitis, retinal detachment, and transient increases in intraocular pressure. Izervay is also associated with increased rates of neovascular or wet age-related macular degeneration. Patients are monitored for new vision changes and signs of these ocular complications.
Izervay treats geographic atrophy secondary to age-related macular degeneration.
The recommended dose is 2 mg in 0.1 mL by intravitreal injection into each affected eye once monthly.
Yes. Transient increases in intraocular pressure can occur after intravitreal injection.
Yes. Clinical trials showed increased rates of neovascular or wet age-related macular degeneration in treated patients.
Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results From the GATHER2 Phase 3 Trial. https://pubmed.ncbi.nlm.nih.gov/41407269/. Date Accessed October 5, 2026.
Drug Trials Snapshots: IZERVAY. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-izervay. Date Accessed October 5, 2026.
Efficacy and Safety of Avacincaptad Pegol in Patients With Geographic Atrophy (GATHER2): 12-Month Results From a Randomised, Double-Masked, Phase 3 Trial. https://pubmed.ncbi.nlm.nih.gov/37696275/. Date Accessed October 5, 2026.
IZERVAY (Avacincaptad Pegol) Prescribing Information. https://www.astellas.com/content/dam/astellas-com/global/en/documents/us-ophthalmology-izervay-prescribing-information.pdf. Date Accessed October 5, 2026.
IZERVAY (Avacincaptad Pegol) Prescribing Information. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1642fe6a-dc26-4d20-ae6e-654af744e3bd. Date Accessed October 5, 2026.